These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31566226)

  • 1. Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system.
    Kosse LJ; Jessurun NT; Hebing RCF; Huiskes VJB; Spijkers KM; van den Bemt BJF; Nurmohamed MT
    Rheumatology (Oxford); 2020 Jun; 59(6):1253-1261. PubMed ID: 31566226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.
    Gabay C; Riek M; Scherer A; Finckh A;
    Rheumatology (Oxford); 2015 Sep; 54(9):1664-72. PubMed ID: 25922549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.
    Bergstra SA; Branco JC; Vega-Morales D; Salomon-Escoto K; Govind N; Allaart CF; Landewé RBM
    Ann Rheum Dis; 2018 Oct; 77(10):1413-1420. PubMed ID: 29980576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
    Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
    Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated inflammatory disease patients' preferences in adverse drug reaction information regarding biologics.
    Kosse LJ; Weits G; Vonkeman HE; Spuls PI; Van Den Bemt BJF; Tas SW; Hoentjen F; Nurmohamed MT; Van Doorn MBA; Van Puijenbroek EP; Jessurun NT
    Expert Opin Drug Saf; 2020 Aug; 19(8):1049-1054. PubMed ID: 32524887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
    Pontifex EK; Dissanayake K; Bursill D; Gill T
    Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
    Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
    Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
    Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
    PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
    Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
    Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
    Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
    Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD.
    Putrik P; Ramiro S; Lie E; Keszei AP; Kvien TK; van der Heijde D; Landewé R; Uhlig T; Boonen A
    Rheumatology (Oxford); 2016 Jul; 55(7):1217-24. PubMed ID: 27012686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.
    Chandrashekara S; Shobha V; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Rheumatol Int; 2019 Mar; 39(3):497-507. PubMed ID: 30684040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.
    Olsen IC; Lie E; Vasilescu R; Wallenstein G; Strengholt S; Kvien TK
    Rheumatology (Oxford); 2019 Mar; 58(3):481-491. PubMed ID: 30508189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
    Sozeri B; Ulu K; Kaya-Akça U; Haslak F; Pac-Kisaarslan A; Otar-Yener G; Baba O; Altug-Gucenmez O; Sahin N; Bağlan E; Sönmez HE; Cakmak F; Ozturk K; Gezgin-Yıldırım D; Şener S; Barut K; Batu ED; Yıldız M; Basaran O; Adrovic A; Sahin S; Ozdel S; Bilginer Y; Poyrazoglu MH; Demir F; Yuksel S; Kalyoncu M; Kasapcopur O; Ozen S; Aktay-Ayaz N
    Rheumatol Int; 2022 Mar; 42(3):469-475. PubMed ID: 34570263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.